Log In
BCIQ
Print this Print this
 

Yisaipu, biosimilar etanercept

  Manage Alerts
Collapse Summary General Information
Company Shanghai CP Guojian Pharmaceutical Co. Ltd.
DescriptionBiosimilar version of Enbrel etanercept, a recombinant p75 tumor necrosis factor (TNF) receptor linked to the Fc portion of human IgG1 (TNFr:Fc)
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of ActionBiosimilar
Therapeutic ModalityBiologic: Fusion protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$219.4M

$219.4M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/20/2014

$219.4M

$219.4M

0

Get a free BioCentury trial today